Eversept Partners’s Exelixis EXEL Stock Holding History

Eversept Partners’s Portfolio EXEL Stock Details EXEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-203,156	Closed	-$4.61M	–	87
2022 Q1	$4.61M	Sell	203,156 -332,544	-62%	-$6.5M	0.35%	48
2021 Q4	$9.79M	Buy	535,700 +19,393	+4%	+$371K	0.63%	43
2021 Q3	$10.9M	Buy	516,307 +336,307	+187%	+$6.25M	0.75%	38
2021 Q2	$3.28M	Buy	+180,000	New	+$4.2M	0.22%	56

Other funds holding EXEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Eversept Partners's EXEL Position: Q2 2022 in Review

Eversept Partners sold out of Exelixis (EXEL) in Q2 2022, closing a stake of 203,156 shares — an estimated $4.61M sold.

Eversept Partners first reported a position in EXEL in Q2 2021 and held it in 4 quarters. The position peaked at $10.9M in Q3 2021. 373 funds tracked by Wall St. Rank hold EXEL as of Q2 2022.

Eversept Partners reported no remaining Exelixis position as of Q2 2022 after selling out during the quarter.
Eversept Partners sold 203,156 Exelixis shares in Q2 2022, an estimated $4.61M.
Eversept Partners first reported a position in Exelixis in Q2 2021 and held it in 4 quarters.
Eversept Partners's Exelixis position peaked at $10.9M in Q3 2021.
373 funds tracked by Wall St. Rank held Exelixis as of Q2 2022.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.